Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment

Stern, Martin; Hirsch, Hans; Cusini, Alexia; Van Delden, Christian; Manuel, Oriol; Meylan, Pascal; Boggian, Katia; Mueller, Nicolas J; Dickenmann, Michael

doi:10.1097/TP.0000000000000160

Scientific article

English

Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment

ContributorsStern, Martin; Hirsch, Hans; Cusini, Alexia; Van Delden, Christian; Manuel, Oriol; Meylan, Pascal; Boggian, Katia; Mueller, Nicolas J; Dickenmann, Michael

Published inTransplantation, vol. 98, no. 9, p. 1013-1018

Publication date2014

Abstract

Cytomegalovirus (CMV) replication has been associated with more risk for solid organ graft rejection. We wondered whether this association still holds when patients at risk receive prophylactic treatment for CMV.

Affiliation

Research group

Citation (ISO format)

STERN, Martin et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. In: Transplantation, 2014, vol. 98, n° 9, p. 1013–1018. doi: 10.1097/TP.0000000000000160

Article (Published version)

Identifiers

PID : unige:41715
DOI : 10.1097/TP.0000000000000160
PMID : 24837540

ISSN of the journal0041-1337

569views

0downloads

Creation11/11/2014 3:16:00 PM

First validation11/11/2014 3:16:00 PM

Update time03/14/2023 10:14:22 PM

Status update03/14/2023 10:14:22 PM

Last indexation08/29/2023 1:04:00 PM

Archive ouverte UNIGE

Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment

Cytomegalovirus (CMV) replication has been associated with more risk for solid organ graft rejection. We wondered whether this association still holds when patients at risk receive prophylactic treatment for CMV.

Technical informations